Important new paper from @neurosurgerynm.bsky.social and several collaborators reveals critical features of the chordoma immune landscape and lays the foundation for chordoma patients to benefit from immunotherapy advances. 🧵

academic.oup.com/neuro-oncolo...

monitoring the situation as a shipment of precious chordoma samples from our biobank flys to Melbourne for our collaborators in the Firestein lab at @hudsonresearch.bsky.social ✈️ 🇦🇺

Positive results are celebrated, but we think sharing negative results is important too. In case helpful to anyone, here are compounds we tested in vitro in recent months which didn't show substantial activity as single agents or synergy with known active compounds:

figshare.com/authors/Chor...

We’re hiring for a new role on our research team. It'll be an opportunity to advance interesting science, to work in a nimble and empowering environment, and, to make a tangible impact in the lives of patients in urgent need of new treatment options. www.linkedin.com/jobs/view/42...

The TBXT rs2305089 SNP links the benign notochordal cell tumour and chordoma
pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/...

Interesting new challenge similar in spirit to the well known CACHE!!

For all the gains AI affords in compound design and discovery, experimental validation still remains a bottleneck. But we're making that part easy for the cancer target TBXT with a suite of biophysical, in vitro and in vivo assay capabilities—plus prizes for potent binders: tbxtchallenge.org

📰 Prof Paul Workman, our former CEO, along with his team in our Centre for Cancer Drug Discovery, have made a breakthrough that could lead to new drugs for #chordoma — a rare #BoneCancer that led to the death of his mother.

Read more in @theguardian.com ⤵️

www.theguardian.com/science/2025...

Crucial building blocks for drugging TBXT (brachyury) published by @ox.ac.uk @icr.ac.uk @uncchapelhill.bsky.social team including crystal structure, discovery of ligandable pockets, and compounds that could serve as starting points for inhibitors or degraders www.nature.com/articles/s41...

#chemsky & #compchem peeps, we need your help drugging a difficult target: TBXT (brachyury), a transcription factor critical for our disease, chordoma, and implicated in other cancers. We can offer enabling resources, free SPR analysis and now $500K+ in prizes for TBXT ligands: tbxtchallenge.org

#chemsky & #compchem peeps, we need your help drugging a difficult target: TBXT (brachyury), a transcription factor critical for our disease, chordoma, and implicated in other cancers. We can offer enabling resources, free SPR analysis and now $500K+ in prizes for TBXT ligands: tbxtchallenge.org

Our team recently attended the Connective Tissue Oncology Society (CTOS) annual meeting and presented on three areas of ongoing research in the lab: targeting replication stress, biomarkers of EGFR inhibitor sensitivity, and capabilities to enable TBXT (brachyury) drug discovery. 🧵

Nice work from @dkfz.bsky.social defining TBXT regulome.

Building on recent findings that GPX4 is a genetic essentiality in chordoma, we’ve demonstrated that GPX4 inhibition induces ferroptotic cell death, suggesting #ferroptosis susceptibility may be a targetable vulnerability in chordoma. Results now on Figshare:
figshare.com/articles/fig...

Confirmed our recent observation of synergism between gemcitabine and ATR inhibition in two additional cell lines, latest data now on Figshare figshare.com/articles/fig...

We're studying replication stress in chordoma, and have recently identified several therapeutic approaches that exploit this vulnerability. Here are 3 new figures we’ve put on Figshare to enable others to build on our findings before they’re published. 👇

Hi! We're joining @bsky.app from Twitter. Our feed there is at x.com/CFLabsResearch. We're here to share recent developments from our lab and from the broader chordoma research field, as well as to connect with and learn from others with overlapping research interests/expertise.